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Abstract
Background: The prevalence of asthma in industrialized countries has been increasing dramatically and asthma is
now the most common chronic disease of children in the United States. The rapidity of the increase strongly
suggests that changes in environmental exposures are the likely cause of this epidemic. Further, the early onset of
allergic manifestations suggests that these exposures may act on the prenatal development of the immune system.
We have focused on the potential effects of bisphenol A (BPA), a chemical pollutant with one of the largest
productions, on the development of childhood asthma. We have reported that perinatal BPA exposure promotes
the development of allergic asthma in a mouse model. The current study was designed to identify a critical period
of BPA exposure and to begin elucidating the mechanisms for this susceptibility.
Methods: Female BALB/c mice received 10 micro g/ml BPA in their drinking water from one week before
pregnancy until the end of the study. Some of the pups were transferred in the first 48 h of life from their BPA-
loaded mother to an unexposed mother, or vice versa. Half of the pups were sensitized with a low dose of the
experimental allergen ovalbumin (OVA), the rest received PBS as an unsensitized controls. On day 22, the pups
were challenged by inhalations of ovalbumin or PBS followed by quantification of eosinophils in and
hyperreactivity of their airways, major indicators of experimental asthma in this classical mouse model. Hepatic
expression of two isoforms of UDP-glucuronosyltransferase (Ugt) was quantified by quantitative RT-PCR at various
ages.
Results: Pups exposed to BPA in utero and through breast milk, or in utero only, displayed an asthma phenotype
in response to their “suboptimal” allergic sensitization, whereas, pups only exposed to BPA postnatally from breast
milk, did not. The expression of Ugt2b1, an isoform related to BPA clearance in rats, was not detectable in mouse
fetuses and newborn pups, but increased by day 5 and approached adult levels by day 25.
Conclusions: Prenatal exposures that produce environmentally relevant burdens of BPA, followed by postnatal
allergic sensitization and challenges, promote the development of experimental allergic asthma. Delayed
expression of BPA-metabolizing enzymes may explain, at least in part, the enhanced fetal susceptibility to this
common environmental contaminant.
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The production of the industrial chemical bisphenol A
(BPA) is one of the largest in the world (approximately
2.4 billion pounds in 2007 [1]). BPA has been used for
over 40 years to make hard plastic products, such as,
baby bottles, food-storage containers, lining for food
and beverage containers, and dental sealants. The estro-
genic effects of BPA in experimental animals make it a
potential endocrine disruptor [2,3]. In January 2010, the
US Food and Drug Administration (FDA) changed its
stance on BPA toxicity from “posed no risk for humans”
to indicate that exposure to the chemical is of “some
concern” for infants and children [4].
Since newborn humans and mice generally have a Th2
skewed pattern of immune responses, they are more
prone to develop allergic diseases until “immune-matur-
ing” infections promote a shift toward Th1 responses
[5]. Like estradiol, environmental estrogen exposure in
utero might influence the development of the immune
system during important transition periods [6]. Endo-
genous and environmental estrogens promote Th2
responses in mice, as indicated by increased production
of IL-4, transcription factor GATA-3, and MHC class II
expression and decreasing IFN-g production by CD4
+CD8
+ thymocytes, naïve CD4
+ T cells, and spleen den-
dritic cells [7,8]. Early exposure to BPA is particularly
associated with heighted inflammation. Prenatal [9] and
e a r l yp o s t n a t a l[ 1 0 ]e x p o s u r eo fm i c ep r o m o t e sT h 2
polarization (e.g. increased IL-4 and reduced IFN-g).
Prenatal exposure to BPA is also associated with
reduced percentages of T regulatory CD4 + CD25+ cells
[9] which are associated with atopy. We postulated that
perinatal exposure to environmental estrogens might
enhance or maintain the Th2 skewed pattern during
this period of rapid immunologic transition.
We recently reported that a combination of pre-and
postnatal exposures to maternally-derived BPA which
produced environmentally relevant BPA burdens in
mouse pups, promotes the development of allergic
asthma in a mouse model [11]. Pups born to and nursed
by mothers exposed to BPA in their drinking water
responded to a “suboptimal” allergenic sensitization pro-
tocol by producing higher concentrations of serum IgE
anti-ovalbumin (OVA) antibodies, numbers of bronchial
eosinophils, and airway hyperreactivity (AHR), relative
to pups born to and nursed by mothers that were not
exposed to BPA.
We felt it was important to further define the critical
period(s) during which BPA exposure might promote
the development of childhood asthma and thus hypothe-
sized that prenatal exposures to BPA were critical to
promote the development of asthma. The dose of BPA
we used produces internal doses of BPA in the mother
mice and their pups that are similar to those in inadver-
tently-exposed humans [12]. To separate the prenatal
and early-postnatal effect of BPA in our experimental
model, some of the infant mice were transferred from
BPA-loaded birth mothers to unexposed foster mothers,
or vice versa, within 48 h after birth. After allergic sensi-
tization and challenge, the pups were assessed for bron-
chial hyperreactivity. Further, we explore here metabolic
mechanisms that might enhance the susceptibility of the
mouse pups to BPA, by assessing the expression of a
major enzyme that metabolizes BPA. Thus, we have
tested the hypothesis that delayed expression of BPA
metabolizing enzymes in the fetus enhances its exposure




Since human fetuses and young children are Th2 domi-
nant, we chose for our studies BALB/c mice, which have
been shown to have Th2 dominant immune responses
[13]. Male and female BALB/c mice were obtained from
Harlan (Houston, TX) and were housed in pathogen-
free conditions in the animal research facility of the
University of Texas Medical Branch (UTMB; Galveston,
TX) in accordance with the National Institutes of Health
and UTMB institutional guidelines for animal care. Each
mother and her litter were housed separately and fed a
casein-based diet (Research Diet, New Brunswick, NJ) to
eliminate estrogenic exposure from the typical soy-based
mouse diet from one week before BPA loading until the
end of the study [11]. We used animal cages made of
polysulfone (Tecniplast, Buguggiate, Italy) and bottled
water, previously shown to be free of detectable levels of
BPA [11].
Experimental model of asthma
Our protocol for BPA-loading and allergic sensitization,
shown in Figure 1 was a modification of our previously
published protocol [11]. Adult female mice were given
10 μg/ml of BPA (Sigma, St. Louis, MO) in their drink-
ing water from one week before mating, until the end of
the experiments. Some of the pups were transferred
within 48 h after birth from BPA-loaded birth mother
to unexposed foster mothers,a n dv i c ev e r s a[ 1 4 ] .T h i s
manipulation resulted in four groups of pups, based on
their BPA exposure, BPA-BPA: both prenatal and post-
natal exposure to BPA, BPA-N: only prenatal exposure,
N-BPA: only postnatal and N-N: no BPA exposure.
Pups sensitized to OVA using our “suboptimal” protocol
[11] formed the experimental groups and non-sensitized
pups with the same BPA exposures served as controls
for independent effects of BPA on lung function. Forty-
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AHR to methacholine was assessed in all pups by the
forced oscillation technique (flexiVent; SCIREQ, Mon-
treal, Quebec, Canada) as we described [11].
Quantifying the inflammatory cells in bronchoalveolar
lavage (BAL) fluid
Immediately after sacrifice, cells in the lungs were recov-
ered by flushing the isolated trachea with 0.5 mL PBS.
Total leukocytes were counted using a hemocytometer.
Eosinophil counts were calculated from differential cell
counts on 150 μL of the fluid deposited onto glass
slides, using a Cytospin 3 centrifuge (400 × g for 4 min;
Shandon Lipshaw, Pittsburgh, PA) and stained with
hematoxylin and eosin [11]. The results were expressed
as the absolute number of the total cells and eosinophils
recovered.
Serum BPA
We quantified total BPA concentrations by ELISA (IBL
America, Minneapolis, MN) in the sera from 22 day-old
pups exposed to BPA both pre- and postnatally.
Quantification of hepatic mRNA expression of Ugt2b1
and Ugt1a1
Gestational day (GD) 1 was considered the day when
the vaginal plug was detected. Liver samples were har-
vested from untreated fetal mice on gestational day
(GD) 17 and 19, infant pups on postnatal day (PND) 0,
5, 15 and 25 and adult mice after the age of 9 weeks.
Liver samples were immediately stabilized by RNA later
reagent (QIAGEN, Valencia, CA) and frozen at -80°C.
Total RNA Isolation
Approximately 30 mg samples of liver were disrupted
and homogenized in TRIZOL (Invitrogen, Carlsbad, CA)
using 21 gauge needles and syringes. Total RNA was
purified using RNeasy Mini Kit (QIAGEN, Valencia,
CA). RNA was quantified by UV photometry at 260 nm
and the purity and integrity were confirmed by their
OD 260/280 ratio and visualization of 18S and 28S
rRNA bands on the ethidium bromide gels.
RT-Real-time PCR
We quantified mRNA expression for two isotypes of
glucuronyl transferases in these livers using real-time
PCR as we described [15]. cDNA was synthesized from
total RNA using High-Capacity cDNA Reverse Tran-
scription Kits (Applied Biosystems, Foster City, CA)
according to the manufacturer’s protocol. FAM dye-
labeled TaqMan Gene Expression Assays, including
gene-specific polymerase chain reaction (PCR) primers
and dye-labeled probes, specific for mouse Ugt1a1
(Mm02603337_m1), Ugt2b1 (Mm00514184_m1), and
mouse glyceraldehydes-3-phosphate dehydrogenase
(Mm99999915_g1) were purchased from Applied
Biosystems.
Real-time reactions composed of cDNA, gene-specific
20X TaqMan probes with Deoxynucleotide Solution
Mix (New England BioLabs) and Taq DNA Polymerase
(New England BioLabs) were performed in duplicate.
Reaction conditions were as follows: initial setup at 50°C
for 2 min and at 95°C for 10 min, followed by 45 cycles
of 95°C for 15 sec, and 60°C for 1 min. Real-time reac-
tions were performed on iQ5 Multicolor Real-time PCR
Detection system (BIO-RAD) and data were obtained as
Ct values. Data were analyzed by the ΔΔCt method
using glyceraldehydes-3-phosphate dehydrogenase as an
internal control for each sample. mRNA from a single
adult male liver served as the reference.
Statistical analysis
The pregnant mouse dam was the experimental unit for
all experiments. Results for the pups from each dam are
expressed as the mean ± SE. Statistical analysis was per-
formed using one-way analysis of variance. Where dif-
ferences between groups were present, the elements that
differed were identified by the Student’s t-test. Differ-
ences at p < 0.05 were defined as statistically significant.
Results
BPA exposure and bronchial hyperreactivity to
methacholine
Figure 2 shows that maternal exposure to BPA
enhanced the development of AHR in the lungs of those
pups that were exposed to BPA in utero only, and in
utero and postnatally though breast milk, compared
with pups that were only exposed to BPA postnatally, or
not exposed to BPA at all (p < 0.05). Mice that were not
Figure 1 Maternal BPA loading and OVA sensitization and
challenge, and (B) AHR of the pups. Some of the pups were
transferred from BPA loaded to non-exposed mothers, and vice
versa, prior to sensitization with OVA
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of BPA exposure on their AHR (data not shown).
Effects of BPA on airway inflammation
To determine whether BPA alters allergen-induced pul-
monary inflammation, we quantified total cells and eosi-
nophils in BAL fluid. We observed a significant increase
in eosinophils in BAL fluids from OVA sensitized pups
exposed to BPA only in utero, p =0 . 0 3v s .n o nB P A
exposed group and those exposed in utero and postnatal
BPA, p < 0.01 vs. the non BPA exposed group (Figure
3). There were no significant differences in total cell
numbers between any groups.
Expression of glucuronosyltransferases enzymes during
pre-and postnatal development
As shown in Figure 4, the expression of mRNA for both
isoforms of Utg was very low (around 0.1% of adult
level) early in fetal development. However Ugt1a1, the
main bilirubin metabolizing isoform, increased rapidly
by gestational day 17 to achieve near adult levels at
birth. In contrast, Ugt2b, an isoform related to BPA
clearance in rats [16], increased much more slowly in
utero and did not approach adult levels of expression
until PND 5.
Serum BPA in the pups
The concentrations of total BPA in the serum of 22 day-
old pups that were born to exposed dams whose drink-
ing water contained 10 μg/ml of BPA for a total of
approximately 50 days (7 days before pregnancy, 21 days
during pregnancy and 22 day postpartum) had a range
of 29-39 (31 ± 4) ng/ml.
Discussion
We originally embarked on studies of environmental
estrogens in asthma pathogenesis [17,18] based on
extensive epidemiological evidence that there are major
differences in asthma susceptibility between men and
women during different life stages, with males predomi-
nating (male: female ratio = 3:1) from infancy to age 14
and females predominating (1:3) from ages 18 to 34
[19]. Further, hormone replacement therapy (especially
with estrogens) in women enhances both new onset [20]
and worsening of previously quiescent asthma [21], sug-
gesting that estrogenic agent may play a role in the gen-
der difference in asthma prevalence. A molecular basis
Figure 2 AHR assessed with methacholine.N :n o r m a lw a t e r .R :
airway resistance. BPA-BPA: both prenatal and postnatal exposure to
BPA, BPA-N: only prenatal exposure, N-BPA: only postnatal and N-N:
no BPA exposure. Data are expressed as mean ± SE (n = 5-11
litters). There was no significant difference between any of the non
OVA-sensitized groups. *p < 0.05 compared with BPA non exposed
and OVA sensitized groups
Figure 3 BPA effects on OVA induced airway inflammation.
Eosinophil counts in BAL fluid 18 days after i.p. injection of OVA.
Bars indicate the mean ± SE for groups. N = 4-9 litters. *p = 0.03
and **p < 0.01 compared with OVA-sensitized pups from non BPA
exposed mothers. *** The eosinophil number in one BAL fluid was
5SE greater than the mean of the other samples. It was considered
an outlier and not included in the statistics. There was no significant
difference between any of the non OVA-sensitized groups
Figure 4 Relative Ugt1a1 (A) and Ugt2b1 (B) expression as
determined by real-time PCR on RNA purified from mouse
livers. Data are relative to standard mRNA from one adult male and
computed by the ΔΔCt method. Data are mean ± SE (pup: n = 4-7
litters, adult; n = 10). *p < 0.05 and **p < 0.005 between groups.
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gested by our and our colleagues’ finding that immune
cells, including mast cells and lymphocytes from
humans and mice, expressed estrogen receptor (ER)a,
but not ERb [8,17]. Expression of ERa was required for
environmental estrogens, including nonylphenol, an
alkylphenol, to enhance basophil degranulation [18].
BPA also has a high affinity to estrogen-related receptor
(ERR)g [22], but ERRg has yet to be described on any
immune cells. We also detected G-protein coupled
receptor 30 (GPR30) on mast cells (unpublished obser-
vation from Dr. Peter Thomas). Androgen receptor (AR)
was detected by others on mast cells and lymphocytes
[23,24]. Aryl hydrocarbon receptor (AhR) was also
detected on lymphocytes, but not on mast cells, but the
relationship between AHR, ERs and estrogens is quite
complex.
In our previous study, we demonstrated that pups that
were born to and nursed by dams that were exposed to
BPA had an enhanced propensity to develop asthma
after an intentionally “suboptimal” allergic sensitization
during infancy [11,25]. In the current study, we trans-
ferred some pups from BPA-loaded birth mothers to
unexposed foster mothers and vice versa, within 48 h
after their birth [14]. These transfers created four
groups of pups that allowed us to test our hypothesis
that the prenatal exposures to BPA were required to
promote the development of allergic asthma in our
mouse model. Consistent with this hypothesis, only the
pups exposed to BPA prenatally demonstrated enhanced
airway inflammation and hyperreactivity. These results
strongly suggest that prenatal life is a critical period,
during which BPA exposure promotes the development
of asthma. However, as we previously observed [11],
mice that are exposed to BPA, but not sensitized to
OVA did not develop an asthma phenotype, suggesting
that prenatal BPA exposure enhances the allergic com-
ponent of asthma pathogenesis.
We chose the concentration of BPA to feed dams
based on a previous report that this dose, fed for a simi-
larly short period of time, produces a BPA burden
(internal dose) with a mean of 10-25 ng/g tissue in
brain, kidney, liver and testis, as measured by GC-MS
analysis [12]. These burdens are similar to those in
human samples, which contained BPA at concentrations
of up to 104.9 ng/g tissue [26]. To confirm the relevance
of this dose in our mouse model to environmental BPA
exposures of humans, we quantified total BPA concen-
trations in the sera of pups that were exposed both pre-
and postnatally to maternal BPA. The range of BPA
concentrations in the sera of the mouse pups 29-39 ng/
ml was only slightly greater than the upper range found
in two studies of plasma BPA in pregnant women (0.5-
22.3 and 0.3-18.9 ng/ml) from the US and Germany
[26,27]. The large variability of BPA concentrations in
human cord blood, likely due to different levels of expo-
sures of their mothers, suggests that some infants may
have in utero BPA burdens similar or greater than those
of our experimentally-exposed mice.
Next, we tested the hypothesis that delayed develop-
ment of BPA metabolizing enzymes in the fetus
enhances fetal exposure to transplacental, unconjugated
(estrogenic) BPA and its immunotoxicity. Steroid hor-
mones, including environmental estrogens like BPA, are
largely metabolized by glucuronidation by UGT and
then excreted through the urine [28]. The mammalian
UGT gene superfamily currently has 117 members that
can be divided into four families, UGT1, UGT2, UGT3
and UGT8 [29]. The UGT1A group share homology
between species, but the UGT2B group is only homolo-
gous between rats UGT2B1 and mice Ugt2b1. In human
liver, UGT2B15 showed the highest activity for BPA glu-
curonidation at low (1.0 μM ≈ 0.2 ng/ml) and high (20
μM ≈ 5 ng/ml) substrate concentration, while UGT1A1,
UGT1A3, UGT1A9, UGT2B4 and UGT2B7 were also
capable of catalyzing BPA glucuronidation, though only
at higher concentration of BPA (20 μM) [30]. In rat
liver, BPA is mainly glucuronidated by UGT2B1 [31].
Because rat UGT2B1 shares homology with mouse
Ugt2b1, it is likely that BPA is mainly glucuronidated by
Ugt2b1 in mouse liver. Thus, we assessed the expression
of Ugt2b1 in mouse fetuses as a possible mechanism of
BPA’s enhancement of asthma development in mouse
pups. Another isoform Ugt1a1, a major enzyme for glu-
curonidation of bilirubin in newborn rats, was used as a
control for hepatic expression of Ugts. Our results indi-
cated that the hepatic expression of Ugt2b1, the isoform
related to BPA clearance in rats [16] was very low
throughout the fetal period in our mice, but increased
rapidly after birth. It is possible that this postnatal
increase in Ugt2b1 expression may have protected the
pups from postnatal effects of BPA-exposure. The
expression of Ugt1a1, the main bilirubin-conjugating
isoforms developed more rapidly in utero and reached
near adult levels at birth, indicating that the expression
of some isoforms are easily detected in the fetal livers of
the mice we studied. Together these results are consis-
tent with the hypothesis that unconjugated BPA may
accumulate during the prenatal period and act as an
endocrine disruptor that alters the course of the rapid
development of the immune system.
The relevance of these metabolic findings in our
mouse model to BPA exposure of the human fetus and
infants has yet to be tested directly. However, expression
of Ugt2B15 [30], which is responsible for glucuronida-
tion of BPA in human liver was not detected at 20
weeks of gestation [32] and glucuronidation of another
estrogen, estrone, by fetal and neonatal human liver
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[33]. Furthermore, high level expression of b-glucuroni-
dase enzymes in the human fetus and placenta, which
can deconjugate BPA glucuronide [34], could also
enhance free BPA concentrations in mothers and their
fetuses. Sulfotransferase (SULT)1A1, a human enzyme
that also metabolizes BPA [35] was detected in human
liver from early gestation [36]. However, high level
expression of sulfatases and b-glucuronidase enzymes,
which deconjugate BPA glucuronide and sulfate are also
present in the human fetus and placenta [34,37], which
could increase the concentration of free BPA in mothers
and their fetuses. Understanding the dynamics of BPA
in the placenta, fetus and neonate will require careful
quantification of BPA and its conjugates in relevant tis-
sues and fluids.
While the low level of prenatal expression of Ugt2b1
we describe here could allow accumulation of unconju-
gated BPA in the pups, and thereby, enhance BPA’s
effects on the development of asthma, other differences
between pre-and postnatal exposures could also be
involved. For instance, the route of BPA exposure (sys-
temic for fetus vs. intestinal for infants), maturation
state of the immune system and susceptibility to epige-
netic alteration, alone or induced by high level exposure
to maternal hormones might also enhance the impact to
prenatal BPA exposures on the development of allergic
asthma. Similarly, the concentration of BPA in the
dam’s milk may have limited the BPA exposure in the
pups which did not receive maternal BPA prenatally.
Conclusions
In conclusion, the results of the experiments we
describe here provide the first evidence that the prenatal
period may be a critical one for BPA to promote the
development of asthma. Developmental delays in the
expression of the BPA-metabolizing enzymes may be at
least one reason for this susceptibility in our mouse
model. Studies of environmental exposures to BPA of
the human fetus may help to explain the ongoing epi-
demic of childhood asthma.
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